$PLX
Protalix BioTherapeutics, Inc. Stock $plx

$plx Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-Q Financial Statement

#000114420413043990 Filed on August 08, 2013

Income Statement

Concept	2013 Q3	2013 Q2	2012 Q2
Revenue	$2.284M	$2.264M	$26.11M
YoY Change	-38.67%	-91.33%	3317.93%
Cost Of Revenue	$1.587M	$1.318M	$3.279M
YoY Change	-32.95%	-59.8%	2384.09%
Gross Profit	$1.772M	$1.746M	$21.98M
YoY Change	-41.38%	-92.06%	-562.72%
Gross Profit Margin	77.58%	77.12%	84.17%
Selling, General & Admin	$1.780M	$2.182M	$3.500M
YoY Change	-19.82%	-37.66%	94.44%
% of Gross Profit	100.45%	124.97%	15.92%
Research & Development	$7.723M	$7.990M	$10.54M
YoY Change	-7.24%	-24.22%	20.26%
% of Gross Profit	435.84%	457.62%	47.97%
Depreciation & Amortization	$870.0K	$890.0K	$930.0K
YoY Change	-4.4%	-4.3%	1.09%
% of Gross Profit	49.1%	50.97%	4.23%
Operating Expenses	$9.503M	$10.17M	$10.54M
YoY Change	14.14%	-3.53%	20.26%
Operating Profit	-$5.645M	-$6.894M	$9.620M
YoY Change	1.53%	-171.66%	-169.37%
Interest Expense	$119.0K	$60.00K	$20.00K
YoY Change		200.0%	-88.89%
% of Operating Profit			0.21%
Other Income/Expense, Net	-$102.0K	$57.00K	$22.00K
YoY Change	-225.93%	159.09%
Pretax Income	-$5.750M	-$6.840M	$9.640M
YoY Change	4.93%	-170.95%	-170.42%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income			0.0%
Net Earnings	-$5.747M	-$6.837M	$9.642M
YoY Change	4.89%	-170.91%	-170.44%
Net Earnings / Revenue	-251.62%	-301.99%	36.92%
Basic Earnings Per Share		-$0.07	$0.11
Diluted Earnings Per Share	-$0.62	-$0.07	$0.10
COMMON SHARES
Basic Shares Outstanding	93.54M shares	92.30M shares	91.53M shares
Diluted Shares Outstanding		92.30M shares	94.88M shares

Balance Sheet

Concept	2013 Q3	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$91.40M	$33.10M	$59.30M
YoY Change	82.07%	-44.18%	34.47%
Cash & Equivalents	$91.40M	$33.13M	$59.28M
Short-Term Investments
Other Short-Term Assets	$4.200M	$3.600M
YoY Change
Inventory	$7.577M	$7.191M	$1.029M
Prepaid Expenses
Receivables	$2.053M	$2.030M	$1.536M
Other Receivables	$4.173M	$3.585M	$4.045M
Total Short-Term Assets	$105.2M	$45.93M	$65.89M
YoY Change	76.57%	-30.29%	28.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.34M	$15.00M	$17.34M
YoY Change	-13.95%	-13.5%	-8.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.600M	$1.400M	$1.100M
YoY Change	45.45%	27.27%	-35.29%
Total Long-Term Assets	$15.96M	$16.37M	$18.41M
YoY Change	-10.35%	-11.08%	-11.04%
TOTAL ASSETS
Total Short-Term Assets	$105.2M	$45.93M	$65.89M
Total Long-Term Assets	$15.96M	$16.37M	$18.41M
Total Assets	$121.2M	$62.31M	$84.30M
YoY Change	56.58%	-26.09%	17.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.300M	$3.900M	$4.500M
YoY Change	-25.0%	-13.33%	-22.41%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$25.23M	$26.63M	$21.33M
YoY Change	23.45%	24.83%	5.08%
LONG-TERM LIABILITIES
Long-Term Debt		$376.0K	$4.680M
YoY Change		-91.97%
Other Long-Term Liabilities	$45.70M	$47.70M	$55.10M
YoY Change	-12.45%	-13.43%	-8.62%
Total Long-Term Liabilities	$112.6M	$47.66M	$55.11M
YoY Change	115.9%	-13.51%	-8.61%
TOTAL LIABILITIES
Total Short-Term Liabilities	$25.23M	$26.63M	$21.33M
Total Long-Term Liabilities	$112.6M	$47.66M	$55.11M
Total Liabilities	$137.9M	$74.29M	$76.44M
YoY Change	89.88%	-2.81%	-5.16%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$16.71M	-$11.99M	$7.863M
YoY Change
Total Liabilities & Shareholders Equity	$121.2M	$62.31M	$84.30M
YoY Change	56.58%	-26.09%	17.25%

Cashflow Statement

Concept	2013 Q3	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	-$5.747M	-$6.837M	$9.642M
YoY Change	4.89%	-170.91%	-170.44%
Depreciation, Depletion And Amortization	$870.0K	$890.0K	$930.0K
YoY Change	-4.4%	-4.3%	1.09%
Cash From Operating Activities	-$8.210M	-$8.110M	$13.12M
YoY Change	2.24%	-161.81%	-372.2%
INVESTING ACTIVITIES
Capital Expenditures	$330.0K	$700.0K	$240.0K
YoY Change	-57.14%	191.67%	-83.1%
Acquisitions
YoY Change
Other Investing Activities	-$90.00K	-$20.00K	$0.00
YoY Change	80.0%		-100.0%
Cash From Investing Activities	-$420.0K	-$720.0K	-$240.0K
YoY Change	-48.78%	200.0%	-83.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	66.93M	30.00K	990.0K
YoY Change	-47907.14%	-96.97%	-3400.0%
NET CHANGE
Cash From Operating Activities	-8.210M	-8.110M	13.12M
Cash From Investing Activities	-420.0K	-720.0K	-240.0K
Cash From Financing Activities	66.93M	30.00K	990.0K
Net Change In Cash	58.30M	-8.800M	13.87M
YoY Change	-748.5%	-163.45%	-320.51%
FREE CASH FLOW
Cash From Operating Activities	-$8.210M	-$8.110M	$13.12M
Capital Expenditures	$330.0K	$700.0K	$240.0K
Free Cash Flow	-$8.540M	-$8.810M	$12.88M
YoY Change	-2.95%	-168.4%	-306.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001006281
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	93537360	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	PROTALIX BIOTHERAPEUTICS, INC.
	dei	Trading Symbol TradingSymbol	PLX
	plx	Depreciation Amortization And Asset Impairment DepreciationAmortizationAndAssetImpairment	1818000	USD
	plx	Depreciation Amortization And Asset Impairment DepreciationAmortizationAndAssetImpairment	1860000	USD
	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	3963000	USD
CY2013Q2	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	1532000	USD
	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	3692000	USD
CY2012Q2	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	1689000	USD
	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	304000	USD
	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	1357000	USD
	plx	Number Of Subsidiaries NumberOfSubsidiaries	2	pure
	plx	Other Gains Losses OtherGainsLosses	1200000	USD
CY2013Q2	plx	Other Gains Losses OtherGainsLosses	800000	USD
	plx	Other Gains Losses OtherGainsLosses	-988000	USD
CY2012Q2	plx	Other Gains Losses OtherGainsLosses	-855000	USD
	plx	Proceeds From Issuance Of Common Stock Net Of Expenses ProceedsFromIssuanceOfCommonStockNetOfExpenses		USD
	plx	Proceeds From Issuance Of Common Stock Net Of Expenses ProceedsFromIssuanceOfCommonStockNetOfExpenses	25478000	USD
	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	11781000	USD
CY2013Q2	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	6458000	USD
	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	15699000	USD
CY2012Q2	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	8855000	USD
	plx	Supplemental Offering And Stock Issuance Costs SupplementalOfferingAndStockIssuanceCosts		USD
	plx	Supplemental Offering And Stock Issuance Costs SupplementalOfferingAndStockIssuanceCosts	150000	USD
CY2013Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	13681000	USD
CY2012Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	11051000	USD
CY2013Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3944000	USD
CY2012Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5267000	USD
CY2013Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2030000	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1410000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	645000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3759000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1780000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7413383	shares
CY2013Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7356464	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1785542	shares
CY2012Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1785542	shares
CY2013Q2	us-gaap	Assets Assets	62306000	USD
CY2012Q4	us-gaap	Assets Assets	78727000	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	45932000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	61170000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33126000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52035000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27001000	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	59280000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-18909000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	32279000	USD
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2012Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
	us-gaap	Cost Of Revenue CostOfRevenue	2289000	USD
CY2013Q2	us-gaap	Cost Of Revenue CostOfRevenue	1318000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	4599000	USD
CY2012Q2	us-gaap	Cost Of Revenue CostOfRevenue	3279000	USD
CY2013Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	9003000	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	9437000	USD
CY2013Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	45115000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	48888000	USD
CY2013Q2	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1373000	USD
CY2013Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	129000	USD
CY2012Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1247000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2012Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	168000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-37000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	120000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	3000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4285000	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2182000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5133000	USD
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3504000	USD
	us-gaap	Gross Profit GrossProfit	4743000	USD
CY2013Q2	us-gaap	Gross Profit GrossProfit	1746000	USD
	us-gaap	Gross Profit GrossProfit	24387000	USD
CY2012Q2	us-gaap	Gross Profit GrossProfit	21979000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3048000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2128000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	406000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	462000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-4207000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3546000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3152000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	750000	USD
CY2013Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4360000	USD
CY2012Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1729000	USD
CY2013Q2	us-gaap	Inventory Net InventoryNet	7191000	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	4039000	USD
CY2013Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	2702000	USD
CY2012Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2118000	USD
CY2012Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	192000	USD
CY2013Q2	us-gaap	Liabilities Liabilities	74292000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	82084000	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	62306000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	78727000	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	26628000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25755000	USD
CY2013Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	47664000	USD
CY2012Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	56329000	USD
CY2013Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	376000	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5425000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26564000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1412000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1091000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17695000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6843000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-11158000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-6837000	USD
	us-gaap	Net Income Loss NetIncomeLoss	3738000	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	9642000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	165000	USD
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	57000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	183000	USD
CY2012Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	22000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11323000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6894000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	3555000	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	9620000	USD
CY2013Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3585000	USD
CY2012Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3686000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	71000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	44000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1341000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1047000	USD
CY2013Q2	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	2173000	USD
CY2012Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	2016000	USD
	us-gaap	Pension And Other Postretirement Benefit Contributions PensionAndOtherPostretirementBenefitContributions	14000	USD
	us-gaap	Pension And Other Postretirement Benefit Contributions PensionAndOtherPostretirementBenefitContributions	14000	USD
	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	93000	USD
	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	133000	USD
CY2009Q4	us-gaap	Proceeds From Collaborators ProceedsFromCollaborators	60000000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	30000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1086000	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15001000	USD
	us-gaap	Revenues Revenues	29974000	USD
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10544000	USD
	us-gaap	Revenues Revenues	5832000	USD
CY2013Q2	us-gaap	Revenues Revenues	2264000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16310000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15744000	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7990000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19391000	USD
CY2012Q2	us-gaap	Revenues Revenues	26113000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2499000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3759000	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	-11986000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-3357000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	-26077000	USD
CY2012Q2	us-gaap	Stockholders Equity StockholdersEquity	7863000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1854000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25388000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	30000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1055000	USD
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
CY2013Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	2967537	shares
CY2012Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3354943	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	92241505	shares
CY2013Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	92297522	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	92670033	shares
CY2012Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	94881167	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	92241505	shares
CY2013Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	92297522	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	89702496	shares
CY2012Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91526224	shares

Files In Submission

Name	View Source	Status
0001144204-13-043990-index-headers.html	Edgar Link	pending
0001144204-13-043990-index.html	Edgar Link	pending
0001144204-13-043990.txt	Edgar Link	pending
0001144204-13-043990-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
plx-20130630.xml	Edgar Link	completed
plx-20130630.xsd	Edgar Link	pending
plx-20130630_cal.xml	Edgar Link	unprocessable
plx-20130630_def.xml	Edgar Link	unprocessable
plx-20130630_lab.xml	Edgar Link	unprocessable
plx-20130630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v351133_10q.htm	Edgar Link	pending
v351133_ex31-1.htm	Edgar Link	pending
v351133_ex31-2.htm	Edgar Link	pending
v351133_ex32-1.htm	Edgar Link	pending
v351133_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLX
Protalix BioTherapeutics, Inc. Stock $plx

2013 Q3 Form 10-Q Financial Statement

#000114420413043990 Filed on August 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX Protalix BioTherapeutics, Inc. Stock $plx

2013 Q3 Form 10-Q Financial Statement

#000114420413043990 Filed on August 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX
Protalix BioTherapeutics, Inc. Stock $plx